Composite kidney outcomes
1 paper2 findings
Associations
2Dapagliflozin
downin humans1RR 0.71
1 study
Dapagliflozin
downin humans1RR 0.71
Dapagliflozin lowers the risk of composite kidney outcomes in humans (RR 0.71, 95% CI: 0.53-0.94).
Reviewcompared with semaglutide
Diabetes, obesity & metabolism17 Sep 2026
Finerenone
downin humans1
1 study
Finerenone
downin humans1
Finerenone lowers the risk of composite kidney outcomes in humans.
Review
Diabetes, obesity & metabolism17 Sep 2026
Latest
5 in 12 monthsDiabetes, Obesity & Metabolism
Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease
Meta-analysis of randomised trialsSGLT2 inhibitors
Journal of Hypertension
Association of visit-to-visit blood pressure variability with kidney disease progression and cardiovascular outcomes in the chronic renal insufficiency cohort (CRIC)
Cohort study of 3,891 peopleKidney
General Hospital Psychiatry
Mental disorders and subsequent kidney function decline: A nationwide cohort study in Japan
Cohort study in peopleMental disorders
Clinical Journal of the American Society of Nephrology
Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort
Cohort study of 1,562 peoplePopulations
ADA Scientific Sessions 2026 Abstract
Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Type 1 Diabetes: A Target Trial Emulation Study
Study in peopleInterventions